News Sequana Medical N.V.

Equities

SEQUA

BE0974340722

Real-time Euronext Bruxelles Other stock markets 07:00:05 2024-06-13 am EDT			5-day change	1st Jan Change
1.47 ^EUR	0.00%		0.00%	-63.25%

Jun. 06	Sequana Medical Announces Data on Alfapump® Safety and Quality of Life to Be Presented At EASL Congress 2024	CI
Apr. 03	Sequana Medical Announces Strong Data from DSR Proof-of-Concept Studies in Heart Failure Published in European Journal of Heart Failure	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sequana Medical announces data on alfapump safety and quality of life to be presented at EASL Congress 2024	Jun. 07	AQ
Sequana Medical Announces Data on Alfapump® Safety and Quality of Life to Be Presented At EASL Congress 2024	Jun. 06	CI
Sequana Medical announces positive outcome of Day 100 meeting with FDA regarding PMA application for alfapump	May. 23	AQ
Sequana Medical N : Draft Remuneration Policy	Apr. 24	PU
Advice of the ad hoc committee of independent directors in accordance with Article 7:179 of the Belgian Companies and Associations Code	Apr. 24	PU
Report of the Board of Directors in accordance with Articles 7:179 and 7:197 of the Belgian Companies and Associations Code	Apr. 22	PU
Special Report of the Board of Directors in accordance with Article 7:199 of the Belgian Companies and Associations Code	Apr. 22	PU
Sequana Medical N : Report of the Board of Directors on the annual accounts for the year ended 31 December 2023	Apr. 22	PU
Sequana Medical N : Statutory annual accounts for the year ended 31 December 2023	Apr. 22	PU
Sequana Medical N : Statutory auditor’s report on the consolidated accounts for the year ended 31 December 2023	Apr. 22	PU
Sequana Medical N : Statutory auditor’s report on the annual accounts for the year ended 31 December 2023	Apr. 22	PU
Sequana Medical Announces Strong Data from DSR Proof-of-Concept Studies in Heart Failure Published in European Journal of Heart Failure	Apr. 03	CI
Sequana Medical NV Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Sequana Medical NV Announces Three Month Follow-Up Data from MOJAVE Non- Randomized Cohort Confirming Significant Improvement in Diuretic Response and Virtual Elimination of Loop Diuretics Following DSR Therapy	Mar. 25	CI
Sequana Medical Raises EUR11.5 Million via Share Placement	Mar. 21	MT
Sequana Medical's Premarket Application for Alfapump Accepted by US FDA; Shares Rise	Jan. 29	MT
Sequana Medical Receives New US Reimbursement Codes for Alfapump System	Jan. 03	MT
Sequana Medical submits Premarket Approval application to US FDA for alfapump in recurrent or refractory ascites due to liver cirrhosis	Dec. 29	AQ
Belgium's Sequana Medical Seeks US FDA Premarket Approval for Liver Ascites Treatment Device	Dec. 28	MT
Sequana Medical N : announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure	Nov. 29	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sequana Medical N.V.

Equities

SEQUA

BE0974340722

Summary

Filters